Zevra Therapeutics ( ZVRA ) Reports Q2 Loss, Tops Revenue Estimates ( Revised )
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -44.75% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Crude Oil Down 1%; Performance Food Group Earnings Top Views - ProFrac Holding ( NASDAQ:ACDC ) , Bolt Projects Holdings ( NASDAQ:BSLK )
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 400 points on Wednesday. The Dow traded up 0.97% to 44,888.04 while the NASDAQ rose 0.14% to 21,711.19. The S&P 500 also rose, gaining, 0.24% to 6,461.26. Health care shares jumped by 1 % on Wednesday.
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently announced acquisition of LAVA Therapeutics.
Zevra Revenue Jumps 486 Percent in Q2
Zevra Therapeutics ( NASDAQ:ZVRA ) , a biopharmaceutical company focused on rare diseases, announced its Q2 2025 financial results on August 12, 2025.The most notable headline was a sharp year-over-year revenue increase and a swing to GAAP profitability, primarily driven by the completion of a ...
Zevra Therapeutics ( ZVRA ) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -104.20% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
What Makes Zevra Therapeutics ( ZVRA ) a Good Fit for 'Trend Investing'
Zevra Therapeutics (ZVRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
CELEBRATION, Fla., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will ...
Zevra Therapeutics ( ZVRA ) Reports Next Week: Wall Street Expects Earnings Growth
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 Company will host conference call at 4:30 p.m. ET, on Tuesday, August ...
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc.
Does Zevra Therapeutics ( ZVRA ) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
CELEBRATION, Fla., July 28, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application ( ...
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group ( SERGG )
CELEBRATION, Fla., July 18, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA® ( MY-PLY-FAH ) ( arimoclomol ) ...
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group ( SERGG ) - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., July 18, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics ( ZVRA ) is a Great Choice
Does Zevra Therapeutics (ZVRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
CELEBRATION, Fla., July 16, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of "Long-term Efficacy and Safety of Arimoclomol ...
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics ( ZVRA ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics ( ZVRA )
Zevra Therapeutics (ZVRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zevra Therapeutics Announces MIPLYFFA® ( arimoclomol ) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
CELEBRATION, Fla., July 11, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, today announced an oral presentation and two poster presentations on ...
Zevra Therapeutics Announces MIPLYFFA® ( arimoclomol ) Featured in Presentations at the National Niemann Pick Disease Foundation Conference - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., July 11, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc.
Zevra Therapeutics ( ZVRA ) Moves 5.1% Higher: Will This Strength Last?
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Zevra's Miplyffa Could Transform Investment Strategies - Zevra Therapeutics ( NASDAQ:ZVRA )
HC Wainwright initiates Zevra with Buy rating, $26 target; cites strong U.S. Miplyffa launch and long-term growth levers. Zevra sold its FDA voucher for $150 million; Miplyffa approved for NPC in Sept. 2024 and could enter EU market by 2026.
This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Amcor ( NYSE:AMCR ) , Cava Group ( NYSE:CAVA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Christopher Carril initiated coverage on CAVA Group, Inc.
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors ...
All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change ...
Zevra Therapeutics ( ZVRA ) Stock Jumps on Strong Q1 Results: What's Going On? - Zevra Therapeutics ( NASDAQ:ZVRA )
Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results. Get our list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
Zevra Therapeutics ( ZVRA ) Reports Q1 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 71.43% and 29.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma ( XERS ) Reports Q1 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 14.29% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., May 06, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ZVRA ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter 2025 ...
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - Zevra Therapeutics ( NASDAQ:ZVRA )
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to Execute Strategic Plan
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team ...
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
CELEBRATION, Fla., April 17, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of "Mechanistic insights into arimoclomol ...
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., April 17, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc.
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., April 07, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ZVRA ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review ...
Zevra Therapeutics Files Preliminary Proxy
Confirms Receipt of Two Director Nominees from Daniel J. ...
Zevra Therapeutics ( ZVRA ) Reports Q4 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -71.79% and 39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of ...
Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C
New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C ...
Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc.
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc.
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
CELEBRATION, Fla., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase ...
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET ...
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - Zevra Therapeutics ( NASDAQ:ZVRA )
Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposium Eight abstracts discussing data and clinical experience associated with MIPLYFFA accepted for poster presentation, with one poster selected for oral presentation by Dr. Eugen Mengel
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual ...
Zevra Therapeutics to Participate at Upcoming Investor Conferences - Zevra Therapeutics ( NASDAQ:ZVRA )
CELEBRATION, Fla., Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ZVRA ( Zevra, or the Company ) , a commercial-stage rare disease therapeutics company, today announced that members of Zevra's executive leadership team will participate in the following February events.
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index ( Nasdaq: NBI ) Effective December 23, 2024
CELEBRATION, Fla., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index ...
Zevra Therapeutics Announces Organizational Changes
CELEBRATION, Fla., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics, Inc. ( NasdaqGS: ZVRA ) ( Zevra, or the Company ) , a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes designed to accelerate its ...
